Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 11, 2007

Ganymed to Use Selexis Tool to Manufacture Antibodies

  • Selexis signed a commercial license agreement with Ganymed Pharmaceuticals for use of Selexis' technology for large-scale production of Ganymed's lead antibodies.

    The deal allows Ganymed to use a high performance cell line, developed by Ganymed scientists using the Selexis SURE cell line development platform, for the clinical and commercial production of a number of products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »